These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15476624)

  • 1. Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteries.
    Hong YJ; Jeong MH; Kim W; Lim SY; Lee SH; Hong SN; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kim H; Kang JC
    Am J Cardiol; 2004 Oct; 94(8):1050-4. PubMed ID: 15476624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction.
    Kim W; Jeong MH; Kim KH; Sohn IS; Hong YJ; Park HW; Kim JH; Ahn YK; Cho JG; Park JC; Cho DL; Kang JC
    J Am Coll Cardiol; 2006 Mar; 47(5):933-8. PubMed ID: 16516074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
    Hausleiter J; Kastrati A; Mehilli J; Schühlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schömig A;
    J Intern Med; 2004 Nov; 256(5):388-97. PubMed ID: 15485474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis.
    Hong YJ; Jeong MH; Hwang SH; Yun NS; Lim SY; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2007 Dec; 123(1):23-8. PubMed ID: 17289173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
    Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model.
    Hong YJ; Jeong MH; Lee SR; Hong SN; Kim KH; Park HW; Kim JH; Kim W; Ahn Y; Cho JG; Park JC; Kang JC
    J Korean Med Sci; 2007 Oct; 22(5):802-9. PubMed ID: 17982226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model.
    Huang Y; Liu X; Wang L; Verbeken E; Li S; De Scheerder I
    Int J Cardiovasc Intervent; 2003; 5(3):166-71. PubMed ID: 12959735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model.
    Lim KS; Jeong MH; Bae IH; Park JK; Park DS; Kim JM; Kim JH; Kim HS; Kim YS; Jeong HY; Song SJ; Yang EJ; Cho DL; Sim DS; Park KH; Hong YJ; Ahn Y
    J Cardiol; 2014 Nov; 64(5):409-18. PubMed ID: 24852847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
    Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease.
    Kim SS; Hong YJ; Jeong MH; Kim W; Kim HK; Ko JS; Lee MG; Sim DS; Park KH; Yoon NS; Yoon HJ; Kim KH; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Song SJ; Cho DL; Kang JC
    Circ J; 2010 Mar; 74(3):442-8. PubMed ID: 20103970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries.
    Buszman P; Milewski K; Zurakowski A; Pajak J; Liszka Ł; Buszman P; Musioł E; AbuSamra M; Trznadel S; Kałuza G
    Kardiol Pol; 2010 May; 68(5):503-9. PubMed ID: 20491008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
    Schömig A; Schmitt C; Dibra A; Mehilli J; Volmer C; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Berger PB; Kastrati A;
    Eur Heart J; 2005 Jul; 26(14):1379-84. PubMed ID: 15734767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetramethylpyrazine-eluting stents prevented in-stent restenosis in a porcine model.
    Ma G; Ding S; Feng Y; Shen C; Chen L; Chen Z
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):201-5. PubMed ID: 17703137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators.
    Circulation; 1999 Aug; 100(8):799-806. PubMed ID: 10458714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biocompatibility of tetramethylpyrazine-eluting stents in normal porcine coronary arteries.
    Ma GS; Chen LJ; Chen Z; Ding S; Shen CX; Feng Y
    Biomed Pharmacother; 2008 Feb; 62(2):125-9. PubMed ID: 17764890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
    Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
    Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses.
    Onuma Y; Serruys P; den Heijer P; Joesoef KS; Duckers H; Regar E; Kukreja N; Tanimoto S; Garcia-Garcia HM; van Beusekom H; van der Giessen W; Nishide T
    Eur Heart J; 2009 Jun; 30(12):1477-85. PubMed ID: 19406868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.